Metamatics

Metamatics is a biotechnology company developing an AI-powered platform for metabolic modeling to accelerate drug discovery and precision medicine. By creating "Metabolic Digital Twins" of patients, the company simulates individual metabolic states using multi-omics data to predict drug responses and identify novel therapeutic targets. Their technology integrates mechanistic systems biology with machine learning to uncover metabolic vulnerabilities in complex diseases, particularly within oncology and metabolic disorders. Metamatics aims to improve clinical trial success rates by enabling better patient stratification and the identification of biomarkers. The company's approach represents a shift toward personalized, data-driven therapeutic development in the life sciences sector.